Form 8-K - Current report:
SEC Accession No. 0001683168-25-002725
Filing Date
2025-04-22
Accepted
2025-04-22 16:05:09
Documents
14
Period of Report
2025-04-17
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K phio_8k.htm   iXBRL 8-K 29150
2 LETTER OF BDO USA P.C, DATED APRIL 21, 2025 phio_ex1601.htm EX-16.1 2340
  Complete submission text file 0001683168-25-002725.txt   206260

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20250417.xsd EX-101.SCH 3020
4 XBRL LABEL FILE phio-20250417_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE phio-20250417_pre.xml EX-101.PRE 22362
16 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 25857707
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)